Key Resources


ASGE Guidelines

ASGE evidence-based guidelines provide clinicians with recommendations for the evaluation, diagnosis, and management of patients undergoing endoscopic procedures of the digestive tract. Guidelines are not a substitute for physicians’ opinion on individual patients. Final decision on an intervention should always be based on local expertise and patient preferences.

All recommendations follow a rigorous process based on a systematic review of medical literature as outlined by the National Academy of Medicine (formerly Institute of Medicine) standards for guideline development.

Whenever possible, guidelines are based on the GRADE (Grading of Recommendation Assessment, Development and Evaluation) methodology.

Panels consist of content experts, stakeholders from other specialties, patient representatives, and members of the ASGE Standards of Practice (SOP) Committee.

Each recommendation is based on consideration of the best medical literature, the balance between risks and benefits, cost-effectiveness, patients’ values, and equity.

Panel members provide ongoing conflict of interest (COI) disclosures, including intellectual conflicts of interest, throughout the development and publication of all guidelines in accordance with the ASGE Policy for Managing Declared Conflicts of Interests.

ASGE strives to provide clinically relevant and practical recommendations, which can help standardize patient care and improve outcomes.

If you have any questions or suggestions, please contact Customer Support at Info@asge.org.

The following information is intended only to provide general information and not as a definitive basis for diagnosis or treatment in any particular case. It is very important that you consult your doctor about your specific condition.

Newly Published

Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium

Sep 27, 2017, 11:39 AM
Barrett’s esophagus (BE) is the only identifiable precursor to esophageal adenocarcinoma (EAC), a malignancy that is associated with an increasing incidence and a dismal 5-year survival rate of 15% to 20%.1-3 BE is characterized by the replacement of normal squamous epithelium of the distal esophagus with metaplastic intestinal-type columnar epithelium.4,5 The presumed step-wise progression of BE to invasive EAC through the histopathologic stages of low-grade dysplasia (LGD), high-grade dysplasia (HGD), and intramucosal EAC provides opportunities to halt the progression and decrease the incidence of BE-related EAC. Abbreviations: ACG (American College of Gastroenterology), ASGE (American Society for Gastrointestinal Endoscopy), BE (Barrett’s esophagus), CE-D (complete eradication of dysplasia), CE-IM (complete eradication of intestinal metaplasia), EAC (esophageal adenocarcinoma), EET (endoscopic eradication therapy), HD-WLE (high-definition white light endoscopy), HGD (high-grade dysplasia), IPR (interpercentile range), IPRAS (interpercentile range adjusted for symmetry), LGD (low-grade dysplasia), RAM (RAND/University of California, Los Angeles Appropriateness Method), RFA (radiofrequency ablation)
Sachin Wani, MD∗, , V. Raman Muthusamy, MD∗ , Nicholas J. Shaheen, MD, MPH , Rena Yadlapati, MD , Robert Wilson, BA , Julian A. Abrams, MD , Jacques Bergman, MD, PhD , Amitabh Chak, MD , Kenneth Chang, MD , Ananya Das, MD , John Dumot, MD , Steven A. Edmundowicz, MD , Glenn Eisen, MD , Gary W. Falk, MD , M. Brian Fennerty, MD , Lauren Gerson, MD, MPH , Gregory G. Ginsberg, MD , David Grande, BA , Matt Hall, PhD , Ben Harnke, MLIS , John Inadomi, MD , Janusz Jankowski, MD , Charles J. Lightdale, MD , Jitin Makker, MD , Robert D. Odze, MD , Oliver Pech, MD , Richard E. Sampliner, MD , Stuart Spechler, MD , George Triadafilopoulos, MD , Michael B. Wallace, MD , Kenneth Wang, MD , Irving Waxman, MD , Srinadh Komanduri, MD, MS
Title : Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium
Doi org link : http://dx.doi.org/10.1016/j.gie.2017.03.010
Volume : Gastrointest Endosc July 2017, Volume 86, Issue 1, Pages 1–17.e3
URL :
Select a choice : Keep
Content created : May 30, 2017, 00:00 AM
File size :
Number :
ExternalPK :

Categories :
  • Ablation
  • Esophagus
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
  • Quality in Endoscopy
  • Quality Indicators
  • Upper GI
Tags :
PIIS0016510717301906
GRADE Guidelines

Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium

Sep 27, 2017, 11:39 AM
Barrett’s esophagus (BE) is the only identifiable precursor to esophageal adenocarcinoma (EAC), a malignancy that is associated with an increasing incidence and a dismal 5-year survival rate of 15% to 20%.1-3 BE is characterized by the replacement of normal squamous epithelium of the distal esophagus with metaplastic intestinal-type columnar epithelium.4,5 The presumed step-wise progression of BE to invasive EAC through the histopathologic stages of low-grade dysplasia (LGD), high-grade dysplasia (HGD), and intramucosal EAC provides opportunities to halt the progression and decrease the incidence of BE-related EAC. Abbreviations: ACG (American College of Gastroenterology), ASGE (American Society for Gastrointestinal Endoscopy), BE (Barrett’s esophagus), CE-D (complete eradication of dysplasia), CE-IM (complete eradication of intestinal metaplasia), EAC (esophageal adenocarcinoma), EET (endoscopic eradication therapy), HD-WLE (high-definition white light endoscopy), HGD (high-grade dysplasia), IPR (interpercentile range), IPRAS (interpercentile range adjusted for symmetry), LGD (low-grade dysplasia), RAM (RAND/University of California, Los Angeles Appropriateness Method), RFA (radiofrequency ablation)
Sachin Wani, MD∗, , V. Raman Muthusamy, MD∗ , Nicholas J. Shaheen, MD, MPH , Rena Yadlapati, MD , Robert Wilson, BA , Julian A. Abrams, MD , Jacques Bergman, MD, PhD , Amitabh Chak, MD , Kenneth Chang, MD , Ananya Das, MD , John Dumot, MD , Steven A. Edmundowicz, MD , Glenn Eisen, MD , Gary W. Falk, MD , M. Brian Fennerty, MD , Lauren Gerson, MD, MPH , Gregory G. Ginsberg, MD , David Grande, BA , Matt Hall, PhD , Ben Harnke, MLIS , John Inadomi, MD , Janusz Jankowski, MD , Charles J. Lightdale, MD , Jitin Makker, MD , Robert D. Odze, MD , Oliver Pech, MD , Richard E. Sampliner, MD , Stuart Spechler, MD , George Triadafilopoulos, MD , Michael B. Wallace, MD , Kenneth Wang, MD , Irving Waxman, MD , Srinadh Komanduri, MD, MS
Title : Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium
Doi org link : http://dx.doi.org/10.1016/j.gie.2017.03.010
Volume : Gastrointest Endosc July 2017, Volume 86, Issue 1, Pages 1–17.e3
URL :
Select a choice : Keep
Content created : May 30, 2017, 00:00 AM
File size :
Number :
ExternalPK :

Categories :
  • Ablation
  • Esophagus
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
  • Quality in Endoscopy
  • Quality Indicators
  • Upper GI
Tags :
PIIS0016510717301906
Upper GI

Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium

Sep 27, 2017, 11:39 AM
Barrett’s esophagus (BE) is the only identifiable precursor to esophageal adenocarcinoma (EAC), a malignancy that is associated with an increasing incidence and a dismal 5-year survival rate of 15% to 20%.1-3 BE is characterized by the replacement of normal squamous epithelium of the distal esophagus with metaplastic intestinal-type columnar epithelium.4,5 The presumed step-wise progression of BE to invasive EAC through the histopathologic stages of low-grade dysplasia (LGD), high-grade dysplasia (HGD), and intramucosal EAC provides opportunities to halt the progression and decrease the incidence of BE-related EAC. Abbreviations: ACG (American College of Gastroenterology), ASGE (American Society for Gastrointestinal Endoscopy), BE (Barrett’s esophagus), CE-D (complete eradication of dysplasia), CE-IM (complete eradication of intestinal metaplasia), EAC (esophageal adenocarcinoma), EET (endoscopic eradication therapy), HD-WLE (high-definition white light endoscopy), HGD (high-grade dysplasia), IPR (interpercentile range), IPRAS (interpercentile range adjusted for symmetry), LGD (low-grade dysplasia), RAM (RAND/University of California, Los Angeles Appropriateness Method), RFA (radiofrequency ablation)
Sachin Wani, MD∗, , V. Raman Muthusamy, MD∗ , Nicholas J. Shaheen, MD, MPH , Rena Yadlapati, MD , Robert Wilson, BA , Julian A. Abrams, MD , Jacques Bergman, MD, PhD , Amitabh Chak, MD , Kenneth Chang, MD , Ananya Das, MD , John Dumot, MD , Steven A. Edmundowicz, MD , Glenn Eisen, MD , Gary W. Falk, MD , M. Brian Fennerty, MD , Lauren Gerson, MD, MPH , Gregory G. Ginsberg, MD , David Grande, BA , Matt Hall, PhD , Ben Harnke, MLIS , John Inadomi, MD , Janusz Jankowski, MD , Charles J. Lightdale, MD , Jitin Makker, MD , Robert D. Odze, MD , Oliver Pech, MD , Richard E. Sampliner, MD , Stuart Spechler, MD , George Triadafilopoulos, MD , Michael B. Wallace, MD , Kenneth Wang, MD , Irving Waxman, MD , Srinadh Komanduri, MD, MS
Title : Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium
Doi org link : http://dx.doi.org/10.1016/j.gie.2017.03.010
Volume : Gastrointest Endosc July 2017, Volume 86, Issue 1, Pages 1–17.e3
URL :
Select a choice : Keep
Content created : May 30, 2017, 00:00 AM
File size :
Number :
ExternalPK :

Categories :
  • Ablation
  • Esophagus
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
  • Quality in Endoscopy
  • Quality Indicators
  • Upper GI
Tags :
PIIS0016510717301906
Lower GI

Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium

Sep 27, 2017, 11:39 AM
Barrett’s esophagus (BE) is the only identifiable precursor to esophageal adenocarcinoma (EAC), a malignancy that is associated with an increasing incidence and a dismal 5-year survival rate of 15% to 20%.1-3 BE is characterized by the replacement of normal squamous epithelium of the distal esophagus with metaplastic intestinal-type columnar epithelium.4,5 The presumed step-wise progression of BE to invasive EAC through the histopathologic stages of low-grade dysplasia (LGD), high-grade dysplasia (HGD), and intramucosal EAC provides opportunities to halt the progression and decrease the incidence of BE-related EAC. Abbreviations: ACG (American College of Gastroenterology), ASGE (American Society for Gastrointestinal Endoscopy), BE (Barrett’s esophagus), CE-D (complete eradication of dysplasia), CE-IM (complete eradication of intestinal metaplasia), EAC (esophageal adenocarcinoma), EET (endoscopic eradication therapy), HD-WLE (high-definition white light endoscopy), HGD (high-grade dysplasia), IPR (interpercentile range), IPRAS (interpercentile range adjusted for symmetry), LGD (low-grade dysplasia), RAM (RAND/University of California, Los Angeles Appropriateness Method), RFA (radiofrequency ablation)
Sachin Wani, MD∗, , V. Raman Muthusamy, MD∗ , Nicholas J. Shaheen, MD, MPH , Rena Yadlapati, MD , Robert Wilson, BA , Julian A. Abrams, MD , Jacques Bergman, MD, PhD , Amitabh Chak, MD , Kenneth Chang, MD , Ananya Das, MD , John Dumot, MD , Steven A. Edmundowicz, MD , Glenn Eisen, MD , Gary W. Falk, MD , M. Brian Fennerty, MD , Lauren Gerson, MD, MPH , Gregory G. Ginsberg, MD , David Grande, BA , Matt Hall, PhD , Ben Harnke, MLIS , John Inadomi, MD , Janusz Jankowski, MD , Charles J. Lightdale, MD , Jitin Makker, MD , Robert D. Odze, MD , Oliver Pech, MD , Richard E. Sampliner, MD , Stuart Spechler, MD , George Triadafilopoulos, MD , Michael B. Wallace, MD , Kenneth Wang, MD , Irving Waxman, MD , Srinadh Komanduri, MD, MS
Title : Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium
Doi org link : http://dx.doi.org/10.1016/j.gie.2017.03.010
Volume : Gastrointest Endosc July 2017, Volume 86, Issue 1, Pages 1–17.e3
URL :
Select a choice : Keep
Content created : May 30, 2017, 00:00 AM
File size :
Number :
ExternalPK :

Categories :
  • Ablation
  • Esophagus
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
  • Quality in Endoscopy
  • Quality Indicators
  • Upper GI
Tags :
PIIS0016510717301906
Biliary and Pancreatic Endoscopy

Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium

Sep 27, 2017, 11:39 AM
Barrett’s esophagus (BE) is the only identifiable precursor to esophageal adenocarcinoma (EAC), a malignancy that is associated with an increasing incidence and a dismal 5-year survival rate of 15% to 20%.1-3 BE is characterized by the replacement of normal squamous epithelium of the distal esophagus with metaplastic intestinal-type columnar epithelium.4,5 The presumed step-wise progression of BE to invasive EAC through the histopathologic stages of low-grade dysplasia (LGD), high-grade dysplasia (HGD), and intramucosal EAC provides opportunities to halt the progression and decrease the incidence of BE-related EAC. Abbreviations: ACG (American College of Gastroenterology), ASGE (American Society for Gastrointestinal Endoscopy), BE (Barrett’s esophagus), CE-D (complete eradication of dysplasia), CE-IM (complete eradication of intestinal metaplasia), EAC (esophageal adenocarcinoma), EET (endoscopic eradication therapy), HD-WLE (high-definition white light endoscopy), HGD (high-grade dysplasia), IPR (interpercentile range), IPRAS (interpercentile range adjusted for symmetry), LGD (low-grade dysplasia), RAM (RAND/University of California, Los Angeles Appropriateness Method), RFA (radiofrequency ablation)
Sachin Wani, MD∗, , V. Raman Muthusamy, MD∗ , Nicholas J. Shaheen, MD, MPH , Rena Yadlapati, MD , Robert Wilson, BA , Julian A. Abrams, MD , Jacques Bergman, MD, PhD , Amitabh Chak, MD , Kenneth Chang, MD , Ananya Das, MD , John Dumot, MD , Steven A. Edmundowicz, MD , Glenn Eisen, MD , Gary W. Falk, MD , M. Brian Fennerty, MD , Lauren Gerson, MD, MPH , Gregory G. Ginsberg, MD , David Grande, BA , Matt Hall, PhD , Ben Harnke, MLIS , John Inadomi, MD , Janusz Jankowski, MD , Charles J. Lightdale, MD , Jitin Makker, MD , Robert D. Odze, MD , Oliver Pech, MD , Richard E. Sampliner, MD , Stuart Spechler, MD , George Triadafilopoulos, MD , Michael B. Wallace, MD , Kenneth Wang, MD , Irving Waxman, MD , Srinadh Komanduri, MD, MS
Title : Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium
Doi org link : http://dx.doi.org/10.1016/j.gie.2017.03.010
Volume : Gastrointest Endosc July 2017, Volume 86, Issue 1, Pages 1–17.e3
URL :
Select a choice : Keep
Content created : May 30, 2017, 00:00 AM
File size :
Number :
ExternalPK :

Categories :
  • Ablation
  • Esophagus
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
  • Quality in Endoscopy
  • Quality Indicators
  • Upper GI
Tags :
PIIS0016510717301906
Adverse Events

Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium

Sep 27, 2017, 11:39 AM
Barrett’s esophagus (BE) is the only identifiable precursor to esophageal adenocarcinoma (EAC), a malignancy that is associated with an increasing incidence and a dismal 5-year survival rate of 15% to 20%.1-3 BE is characterized by the replacement of normal squamous epithelium of the distal esophagus with metaplastic intestinal-type columnar epithelium.4,5 The presumed step-wise progression of BE to invasive EAC through the histopathologic stages of low-grade dysplasia (LGD), high-grade dysplasia (HGD), and intramucosal EAC provides opportunities to halt the progression and decrease the incidence of BE-related EAC. Abbreviations: ACG (American College of Gastroenterology), ASGE (American Society for Gastrointestinal Endoscopy), BE (Barrett’s esophagus), CE-D (complete eradication of dysplasia), CE-IM (complete eradication of intestinal metaplasia), EAC (esophageal adenocarcinoma), EET (endoscopic eradication therapy), HD-WLE (high-definition white light endoscopy), HGD (high-grade dysplasia), IPR (interpercentile range), IPRAS (interpercentile range adjusted for symmetry), LGD (low-grade dysplasia), RAM (RAND/University of California, Los Angeles Appropriateness Method), RFA (radiofrequency ablation)
Sachin Wani, MD∗, , V. Raman Muthusamy, MD∗ , Nicholas J. Shaheen, MD, MPH , Rena Yadlapati, MD , Robert Wilson, BA , Julian A. Abrams, MD , Jacques Bergman, MD, PhD , Amitabh Chak, MD , Kenneth Chang, MD , Ananya Das, MD , John Dumot, MD , Steven A. Edmundowicz, MD , Glenn Eisen, MD , Gary W. Falk, MD , M. Brian Fennerty, MD , Lauren Gerson, MD, MPH , Gregory G. Ginsberg, MD , David Grande, BA , Matt Hall, PhD , Ben Harnke, MLIS , John Inadomi, MD , Janusz Jankowski, MD , Charles J. Lightdale, MD , Jitin Makker, MD , Robert D. Odze, MD , Oliver Pech, MD , Richard E. Sampliner, MD , Stuart Spechler, MD , George Triadafilopoulos, MD , Michael B. Wallace, MD , Kenneth Wang, MD , Irving Waxman, MD , Srinadh Komanduri, MD, MS
Title : Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium
Doi org link : http://dx.doi.org/10.1016/j.gie.2017.03.010
Volume : Gastrointest Endosc July 2017, Volume 86, Issue 1, Pages 1–17.e3
URL :
Select a choice : Keep
Content created : May 30, 2017, 00:00 AM
File size :
Number :
ExternalPK :

Categories :
  • Ablation
  • Esophagus
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
  • Quality in Endoscopy
  • Quality Indicators
  • Upper GI
Tags :
PIIS0016510717301906
Privileging and Credentialing

Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium

Sep 27, 2017, 11:39 AM
Barrett’s esophagus (BE) is the only identifiable precursor to esophageal adenocarcinoma (EAC), a malignancy that is associated with an increasing incidence and a dismal 5-year survival rate of 15% to 20%.1-3 BE is characterized by the replacement of normal squamous epithelium of the distal esophagus with metaplastic intestinal-type columnar epithelium.4,5 The presumed step-wise progression of BE to invasive EAC through the histopathologic stages of low-grade dysplasia (LGD), high-grade dysplasia (HGD), and intramucosal EAC provides opportunities to halt the progression and decrease the incidence of BE-related EAC. Abbreviations: ACG (American College of Gastroenterology), ASGE (American Society for Gastrointestinal Endoscopy), BE (Barrett’s esophagus), CE-D (complete eradication of dysplasia), CE-IM (complete eradication of intestinal metaplasia), EAC (esophageal adenocarcinoma), EET (endoscopic eradication therapy), HD-WLE (high-definition white light endoscopy), HGD (high-grade dysplasia), IPR (interpercentile range), IPRAS (interpercentile range adjusted for symmetry), LGD (low-grade dysplasia), RAM (RAND/University of California, Los Angeles Appropriateness Method), RFA (radiofrequency ablation)
Sachin Wani, MD∗, , V. Raman Muthusamy, MD∗ , Nicholas J. Shaheen, MD, MPH , Rena Yadlapati, MD , Robert Wilson, BA , Julian A. Abrams, MD , Jacques Bergman, MD, PhD , Amitabh Chak, MD , Kenneth Chang, MD , Ananya Das, MD , John Dumot, MD , Steven A. Edmundowicz, MD , Glenn Eisen, MD , Gary W. Falk, MD , M. Brian Fennerty, MD , Lauren Gerson, MD, MPH , Gregory G. Ginsberg, MD , David Grande, BA , Matt Hall, PhD , Ben Harnke, MLIS , John Inadomi, MD , Janusz Jankowski, MD , Charles J. Lightdale, MD , Jitin Makker, MD , Robert D. Odze, MD , Oliver Pech, MD , Richard E. Sampliner, MD , Stuart Spechler, MD , George Triadafilopoulos, MD , Michael B. Wallace, MD , Kenneth Wang, MD , Irving Waxman, MD , Srinadh Komanduri, MD, MS
Title : Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium
Doi org link : http://dx.doi.org/10.1016/j.gie.2017.03.010
Volume : Gastrointest Endosc July 2017, Volume 86, Issue 1, Pages 1–17.e3
URL :
Select a choice : Keep
Content created : May 30, 2017, 00:00 AM
File size :
Number :
ExternalPK :

Categories :
  • Ablation
  • Esophagus
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
  • Quality in Endoscopy
  • Quality Indicators
  • Upper GI
Tags :
PIIS0016510717301906
GI Endoscopy Unit Operations

Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium

Sep 27, 2017, 11:39 AM
Barrett’s esophagus (BE) is the only identifiable precursor to esophageal adenocarcinoma (EAC), a malignancy that is associated with an increasing incidence and a dismal 5-year survival rate of 15% to 20%.1-3 BE is characterized by the replacement of normal squamous epithelium of the distal esophagus with metaplastic intestinal-type columnar epithelium.4,5 The presumed step-wise progression of BE to invasive EAC through the histopathologic stages of low-grade dysplasia (LGD), high-grade dysplasia (HGD), and intramucosal EAC provides opportunities to halt the progression and decrease the incidence of BE-related EAC. Abbreviations: ACG (American College of Gastroenterology), ASGE (American Society for Gastrointestinal Endoscopy), BE (Barrett’s esophagus), CE-D (complete eradication of dysplasia), CE-IM (complete eradication of intestinal metaplasia), EAC (esophageal adenocarcinoma), EET (endoscopic eradication therapy), HD-WLE (high-definition white light endoscopy), HGD (high-grade dysplasia), IPR (interpercentile range), IPRAS (interpercentile range adjusted for symmetry), LGD (low-grade dysplasia), RAM (RAND/University of California, Los Angeles Appropriateness Method), RFA (radiofrequency ablation)
Sachin Wani, MD∗, , V. Raman Muthusamy, MD∗ , Nicholas J. Shaheen, MD, MPH , Rena Yadlapati, MD , Robert Wilson, BA , Julian A. Abrams, MD , Jacques Bergman, MD, PhD , Amitabh Chak, MD , Kenneth Chang, MD , Ananya Das, MD , John Dumot, MD , Steven A. Edmundowicz, MD , Glenn Eisen, MD , Gary W. Falk, MD , M. Brian Fennerty, MD , Lauren Gerson, MD, MPH , Gregory G. Ginsberg, MD , David Grande, BA , Matt Hall, PhD , Ben Harnke, MLIS , John Inadomi, MD , Janusz Jankowski, MD , Charles J. Lightdale, MD , Jitin Makker, MD , Robert D. Odze, MD , Oliver Pech, MD , Richard E. Sampliner, MD , Stuart Spechler, MD , George Triadafilopoulos, MD , Michael B. Wallace, MD , Kenneth Wang, MD , Irving Waxman, MD , Srinadh Komanduri, MD, MS
Title : Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium
Doi org link : http://dx.doi.org/10.1016/j.gie.2017.03.010
Volume : Gastrointest Endosc July 2017, Volume 86, Issue 1, Pages 1–17.e3
URL :
Select a choice : Keep
Content created : May 30, 2017, 00:00 AM
File size :
Number :
ExternalPK :

Categories :
  • Ablation
  • Esophagus
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
  • Quality in Endoscopy
  • Quality Indicators
  • Upper GI
Tags :
PIIS0016510717301906
Screening and Surveillance in Premalignant Conditions

Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium

Sep 27, 2017, 11:39 AM
Barrett’s esophagus (BE) is the only identifiable precursor to esophageal adenocarcinoma (EAC), a malignancy that is associated with an increasing incidence and a dismal 5-year survival rate of 15% to 20%.1-3 BE is characterized by the replacement of normal squamous epithelium of the distal esophagus with metaplastic intestinal-type columnar epithelium.4,5 The presumed step-wise progression of BE to invasive EAC through the histopathologic stages of low-grade dysplasia (LGD), high-grade dysplasia (HGD), and intramucosal EAC provides opportunities to halt the progression and decrease the incidence of BE-related EAC. Abbreviations: ACG (American College of Gastroenterology), ASGE (American Society for Gastrointestinal Endoscopy), BE (Barrett’s esophagus), CE-D (complete eradication of dysplasia), CE-IM (complete eradication of intestinal metaplasia), EAC (esophageal adenocarcinoma), EET (endoscopic eradication therapy), HD-WLE (high-definition white light endoscopy), HGD (high-grade dysplasia), IPR (interpercentile range), IPRAS (interpercentile range adjusted for symmetry), LGD (low-grade dysplasia), RAM (RAND/University of California, Los Angeles Appropriateness Method), RFA (radiofrequency ablation)
Sachin Wani, MD∗, , V. Raman Muthusamy, MD∗ , Nicholas J. Shaheen, MD, MPH , Rena Yadlapati, MD , Robert Wilson, BA , Julian A. Abrams, MD , Jacques Bergman, MD, PhD , Amitabh Chak, MD , Kenneth Chang, MD , Ananya Das, MD , John Dumot, MD , Steven A. Edmundowicz, MD , Glenn Eisen, MD , Gary W. Falk, MD , M. Brian Fennerty, MD , Lauren Gerson, MD, MPH , Gregory G. Ginsberg, MD , David Grande, BA , Matt Hall, PhD , Ben Harnke, MLIS , John Inadomi, MD , Janusz Jankowski, MD , Charles J. Lightdale, MD , Jitin Makker, MD , Robert D. Odze, MD , Oliver Pech, MD , Richard E. Sampliner, MD , Stuart Spechler, MD , George Triadafilopoulos, MD , Michael B. Wallace, MD , Kenneth Wang, MD , Irving Waxman, MD , Srinadh Komanduri, MD, MS
Title : Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium
Doi org link : http://dx.doi.org/10.1016/j.gie.2017.03.010
Volume : Gastrointest Endosc July 2017, Volume 86, Issue 1, Pages 1–17.e3
URL :
Select a choice : Keep
Content created : May 30, 2017, 00:00 AM
File size :
Number :
ExternalPK :

Categories :
  • Ablation
  • Esophagus
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
  • Quality in Endoscopy
  • Quality Indicators
  • Upper GI
Tags :
PIIS0016510717301906
Procedural Management in Endoscopy

Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium

Sep 27, 2017, 11:39 AM
Barrett’s esophagus (BE) is the only identifiable precursor to esophageal adenocarcinoma (EAC), a malignancy that is associated with an increasing incidence and a dismal 5-year survival rate of 15% to 20%.1-3 BE is characterized by the replacement of normal squamous epithelium of the distal esophagus with metaplastic intestinal-type columnar epithelium.4,5 The presumed step-wise progression of BE to invasive EAC through the histopathologic stages of low-grade dysplasia (LGD), high-grade dysplasia (HGD), and intramucosal EAC provides opportunities to halt the progression and decrease the incidence of BE-related EAC. Abbreviations: ACG (American College of Gastroenterology), ASGE (American Society for Gastrointestinal Endoscopy), BE (Barrett’s esophagus), CE-D (complete eradication of dysplasia), CE-IM (complete eradication of intestinal metaplasia), EAC (esophageal adenocarcinoma), EET (endoscopic eradication therapy), HD-WLE (high-definition white light endoscopy), HGD (high-grade dysplasia), IPR (interpercentile range), IPRAS (interpercentile range adjusted for symmetry), LGD (low-grade dysplasia), RAM (RAND/University of California, Los Angeles Appropriateness Method), RFA (radiofrequency ablation)
Sachin Wani, MD∗, , V. Raman Muthusamy, MD∗ , Nicholas J. Shaheen, MD, MPH , Rena Yadlapati, MD , Robert Wilson, BA , Julian A. Abrams, MD , Jacques Bergman, MD, PhD , Amitabh Chak, MD , Kenneth Chang, MD , Ananya Das, MD , John Dumot, MD , Steven A. Edmundowicz, MD , Glenn Eisen, MD , Gary W. Falk, MD , M. Brian Fennerty, MD , Lauren Gerson, MD, MPH , Gregory G. Ginsberg, MD , David Grande, BA , Matt Hall, PhD , Ben Harnke, MLIS , John Inadomi, MD , Janusz Jankowski, MD , Charles J. Lightdale, MD , Jitin Makker, MD , Robert D. Odze, MD , Oliver Pech, MD , Richard E. Sampliner, MD , Stuart Spechler, MD , George Triadafilopoulos, MD , Michael B. Wallace, MD , Kenneth Wang, MD , Irving Waxman, MD , Srinadh Komanduri, MD, MS
Title : Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium
Doi org link : http://dx.doi.org/10.1016/j.gie.2017.03.010
Volume : Gastrointest Endosc July 2017, Volume 86, Issue 1, Pages 1–17.e3
URL :
Select a choice : Keep
Content created : May 30, 2017, 00:00 AM
File size :
Number :
ExternalPK :

Categories :
  • Ablation
  • Esophagus
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
  • Quality in Endoscopy
  • Quality Indicators
  • Upper GI
Tags :
PIIS0016510717301906
Miscellaneous

Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium

Sep 27, 2017, 11:39 AM
Barrett’s esophagus (BE) is the only identifiable precursor to esophageal adenocarcinoma (EAC), a malignancy that is associated with an increasing incidence and a dismal 5-year survival rate of 15% to 20%.1-3 BE is characterized by the replacement of normal squamous epithelium of the distal esophagus with metaplastic intestinal-type columnar epithelium.4,5 The presumed step-wise progression of BE to invasive EAC through the histopathologic stages of low-grade dysplasia (LGD), high-grade dysplasia (HGD), and intramucosal EAC provides opportunities to halt the progression and decrease the incidence of BE-related EAC. Abbreviations: ACG (American College of Gastroenterology), ASGE (American Society for Gastrointestinal Endoscopy), BE (Barrett’s esophagus), CE-D (complete eradication of dysplasia), CE-IM (complete eradication of intestinal metaplasia), EAC (esophageal adenocarcinoma), EET (endoscopic eradication therapy), HD-WLE (high-definition white light endoscopy), HGD (high-grade dysplasia), IPR (interpercentile range), IPRAS (interpercentile range adjusted for symmetry), LGD (low-grade dysplasia), RAM (RAND/University of California, Los Angeles Appropriateness Method), RFA (radiofrequency ablation)
Sachin Wani, MD∗, , V. Raman Muthusamy, MD∗ , Nicholas J. Shaheen, MD, MPH , Rena Yadlapati, MD , Robert Wilson, BA , Julian A. Abrams, MD , Jacques Bergman, MD, PhD , Amitabh Chak, MD , Kenneth Chang, MD , Ananya Das, MD , John Dumot, MD , Steven A. Edmundowicz, MD , Glenn Eisen, MD , Gary W. Falk, MD , M. Brian Fennerty, MD , Lauren Gerson, MD, MPH , Gregory G. Ginsberg, MD , David Grande, BA , Matt Hall, PhD , Ben Harnke, MLIS , John Inadomi, MD , Janusz Jankowski, MD , Charles J. Lightdale, MD , Jitin Makker, MD , Robert D. Odze, MD , Oliver Pech, MD , Richard E. Sampliner, MD , Stuart Spechler, MD , George Triadafilopoulos, MD , Michael B. Wallace, MD , Kenneth Wang, MD , Irving Waxman, MD , Srinadh Komanduri, MD, MS
Title : Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium
Doi org link : http://dx.doi.org/10.1016/j.gie.2017.03.010
Volume : Gastrointest Endosc July 2017, Volume 86, Issue 1, Pages 1–17.e3
URL :
Select a choice : Keep
Content created : May 30, 2017, 00:00 AM
File size :
Number :
ExternalPK :

Categories :
  • Ablation
  • Esophagus
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
  • Quality in Endoscopy
  • Quality Indicators
  • Upper GI
Tags :
PIIS0016510717301906
Guidelines in Spanish

Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium

Sep 27, 2017, 11:39 AM
Barrett’s esophagus (BE) is the only identifiable precursor to esophageal adenocarcinoma (EAC), a malignancy that is associated with an increasing incidence and a dismal 5-year survival rate of 15% to 20%.1-3 BE is characterized by the replacement of normal squamous epithelium of the distal esophagus with metaplastic intestinal-type columnar epithelium.4,5 The presumed step-wise progression of BE to invasive EAC through the histopathologic stages of low-grade dysplasia (LGD), high-grade dysplasia (HGD), and intramucosal EAC provides opportunities to halt the progression and decrease the incidence of BE-related EAC. Abbreviations: ACG (American College of Gastroenterology), ASGE (American Society for Gastrointestinal Endoscopy), BE (Barrett’s esophagus), CE-D (complete eradication of dysplasia), CE-IM (complete eradication of intestinal metaplasia), EAC (esophageal adenocarcinoma), EET (endoscopic eradication therapy), HD-WLE (high-definition white light endoscopy), HGD (high-grade dysplasia), IPR (interpercentile range), IPRAS (interpercentile range adjusted for symmetry), LGD (low-grade dysplasia), RAM (RAND/University of California, Los Angeles Appropriateness Method), RFA (radiofrequency ablation)
Sachin Wani, MD∗, , V. Raman Muthusamy, MD∗ , Nicholas J. Shaheen, MD, MPH , Rena Yadlapati, MD , Robert Wilson, BA , Julian A. Abrams, MD , Jacques Bergman, MD, PhD , Amitabh Chak, MD , Kenneth Chang, MD , Ananya Das, MD , John Dumot, MD , Steven A. Edmundowicz, MD , Glenn Eisen, MD , Gary W. Falk, MD , M. Brian Fennerty, MD , Lauren Gerson, MD, MPH , Gregory G. Ginsberg, MD , David Grande, BA , Matt Hall, PhD , Ben Harnke, MLIS , John Inadomi, MD , Janusz Jankowski, MD , Charles J. Lightdale, MD , Jitin Makker, MD , Robert D. Odze, MD , Oliver Pech, MD , Richard E. Sampliner, MD , Stuart Spechler, MD , George Triadafilopoulos, MD , Michael B. Wallace, MD , Kenneth Wang, MD , Irving Waxman, MD , Srinadh Komanduri, MD, MS
Title : Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium
Doi org link : http://dx.doi.org/10.1016/j.gie.2017.03.010
Volume : Gastrointest Endosc July 2017, Volume 86, Issue 1, Pages 1–17.e3
URL :
Select a choice : Keep
Content created : May 30, 2017, 00:00 AM
File size :
Number :
ExternalPK :

Categories :
  • Ablation
  • Esophagus
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
  • Quality in Endoscopy
  • Quality Indicators
  • Upper GI
Tags :
PIIS0016510717301906

In Progress Guidelines

ASGE Guideline on the Role of Endoscopy in the Management of Malignant Hilar Obstruction

Early 2021

ASGE Guideline on the Management of Cholangitis

Early 2021

ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility

Estimated 2021

ASGE Guideline on the Role of Endoscopic Submucosal Dissection in the Management of Esophageal and Gastric Mucosal Neoplasia

Estimated 2021

Quality in Endoscopy

Quality documents define the indicators of high-quality endoscopy and how to measure it. ASGE quality indicators are based on a rigorous review process which results in valid metrics for evaluating GI endoscopic procedures. 

Quality in Endoscopy

Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium

Sep 27, 2017, 11:39 AM
Barrett’s esophagus (BE) is the only identifiable precursor to esophageal adenocarcinoma (EAC), a malignancy that is associated with an increasing incidence and a dismal 5-year survival rate of 15% to 20%.1-3 BE is characterized by the replacement of normal squamous epithelium of the distal esophagus with metaplastic intestinal-type columnar epithelium.4,5 The presumed step-wise progression of BE to invasive EAC through the histopathologic stages of low-grade dysplasia (LGD), high-grade dysplasia (HGD), and intramucosal EAC provides opportunities to halt the progression and decrease the incidence of BE-related EAC. Abbreviations: ACG (American College of Gastroenterology), ASGE (American Society for Gastrointestinal Endoscopy), BE (Barrett’s esophagus), CE-D (complete eradication of dysplasia), CE-IM (complete eradication of intestinal metaplasia), EAC (esophageal adenocarcinoma), EET (endoscopic eradication therapy), HD-WLE (high-definition white light endoscopy), HGD (high-grade dysplasia), IPR (interpercentile range), IPRAS (interpercentile range adjusted for symmetry), LGD (low-grade dysplasia), RAM (RAND/University of California, Los Angeles Appropriateness Method), RFA (radiofrequency ablation)
Sachin Wani, MD∗, , V. Raman Muthusamy, MD∗ , Nicholas J. Shaheen, MD, MPH , Rena Yadlapati, MD , Robert Wilson, BA , Julian A. Abrams, MD , Jacques Bergman, MD, PhD , Amitabh Chak, MD , Kenneth Chang, MD , Ananya Das, MD , John Dumot, MD , Steven A. Edmundowicz, MD , Glenn Eisen, MD , Gary W. Falk, MD , M. Brian Fennerty, MD , Lauren Gerson, MD, MPH , Gregory G. Ginsberg, MD , David Grande, BA , Matt Hall, PhD , Ben Harnke, MLIS , John Inadomi, MD , Janusz Jankowski, MD , Charles J. Lightdale, MD , Jitin Makker, MD , Robert D. Odze, MD , Oliver Pech, MD , Richard E. Sampliner, MD , Stuart Spechler, MD , George Triadafilopoulos, MD , Michael B. Wallace, MD , Kenneth Wang, MD , Irving Waxman, MD , Srinadh Komanduri, MD, MS
Title : Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium
Doi org link : http://dx.doi.org/10.1016/j.gie.2017.03.010
Volume : Gastrointest Endosc July 2017, Volume 86, Issue 1, Pages 1–17.e3
URL :
Select a choice : Keep
Content created : May 30, 2017, 00:00 AM
File size :
Number :
ExternalPK :

Categories :
  • Ablation
  • Esophagus
  • Gastrointestinal Endoscopy Journal
  • Practice Guidelines
  • Quality in Endoscopy
  • Quality Indicators
  • Upper GI
Tags :
PIIS0016510717301906

Technology Assessments

Technology evaluations provide a review of existing, new, or emerging endoscopic technologies that have an impact on the practice of GI endoscopy. Evaluations are based on a literature review and a search of the MAUDE (U.S. Food and Drug Administration Center for Devices and Radiological Health) database to identify the reported adverse events of a given technology. When financial guidance is indicated, the most recent coding data and list prices at the time of publication are provided.

Technology Assessments
80_logo